NYSE:ABT - Abbott Laboratories Stock Price, Price Target & More

Abbott Laboratories trades on the New York Stock Exchange (NYSE) under the ticker symbol "ABT."

Abbott Laboratories declared a quarterly dividend on Friday, February 16th. Stockholders of record on Friday, April 13th will be paid a dividend of $0.28 per share on Tuesday, May 15th. This represents a $1.12 dividend on an annualized basis and a dividend yield of 1.79%. The ex-dividend date of this dividend is Thursday, April 12th. View Abbott Laboratories' Dividend History.

Abbott Laboratories (NYSE:ABT) announced its quarterly earnings data on Wednesday, April, 18th. The healthcare product maker reported $0.59 EPS for the quarter, topping the Thomson Reuters' consensus estimate of $0.58 by $0.01. The healthcare product maker had revenue of $7.39 billion for the quarter, compared to the consensus estimate of $7.28 billion. Abbott Laboratories had a return on equity of 14.54% and a net margin of 1.67%. The firm's revenue for the quarter was up 16.7% on a year-over-year basis. During the same period in the prior year, the business posted $0.48 earnings per share. View Abbott Laboratories' Earnings History.

Abbott Laboratories is scheduled to release their next quarterly earnings announcement on Thursday, July, 19th 2018. View Earnings Estimates for Abbott Laboratories.

Abbott Laboratories issued an update on its FY18 earnings guidance on Wednesday, April, 18th. The company provided earnings per share guidance of $2.80-2.90 for the period, compared to the Thomson Reuters consensus EPS estimate of $2.86. Abbott Laboratories also updated its Q2 guidance to $0.70-0.72 EPS.

17 equities research analysts have issued 1-year target prices for Abbott Laboratories' stock. Their forecasts range from $56.00 to $80.00. On average, they anticipate Abbott Laboratories' stock price to reach $68.4375 in the next year. View Analyst Ratings for Abbott Laboratories.

Abbott Laboratories saw a increase in short interest during the month of April. As of April 30th, there was short interest totalling 14,602,527 shares, an increase of 52.8% from the April 13th total of 9,557,285 shares. Based on an average daily trading volume, of 6,737,663 shares, the short-interest ratio is currently 2.2 days. Approximately 0.8% of the shares of the company are short sold.

Some companies that are related to Abbott Laboratories include Johnson & Johnson (JNJ), Pfizer (PFE), Novartis (NVS), AbbVie (ABBV), Merck & Co. (MRK), Novo Nordisk A/S (NVO), Bayer (BAYRY), GlaxoSmithKline (GSK), Sanofi (SNY), AstraZeneca (AZN), Eli Lilly And Co (LLY), Bristol-Myers Squibb (BMY), Celgene (CELG), Allergan (AGN) and Shire (SHPG).

News headlines about ABT stock have trended very positive this week, according to Accern. The research group rates the sentiment of press coverage by reviewing more than twenty million news and blog sources in real time. Accern ranks coverage of companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Abbott Laboratories earned a news sentiment score of 0.65 on Accern's scale. They also assigned news headlines about the healthcare product maker an impact score of 48.61 out of 100, indicating that recent press coverage is somewhat unlikely to have an effect on the company's share price in the next few days.

Abbott Laboratories' stock is owned by a number of of institutional and retail investors. Top institutional investors include BlackRock Inc. (6.39%), Massachusetts Financial Services Co. MA (2.28%), Northern Trust Corp (1.49%), Diamond Hill Capital Management Inc. (0.60%), FIL Ltd (0.54%) and Dimensional Fund Advisors LP (0.54%). Company insiders that own Abbott Laboratories stock include Alejandro D Wellisch, Brian B Yoor, Brian J Blaser, Daniel Gesua Sive Salvadori, Daniel J Starks, Deepak S Nath, Heather L Mason, Hubert L Allen, Jaime Contreras, Jared Watkin, Joseph J Manning, Michael J Warmuth, Miles D White, Robert B Ford, Robert E Funck, Roger Bird, Sally E Blount, Sharon J Bracken and Stephen R Fussell. View Institutional Ownership Trends for Abbott Laboratories.

ABT stock was sold by a variety of institutional investors in the last quarter, including Independent Franchise Partners LLP, Massachusetts Financial Services Co. MA, Flossbach Von Storch AG, Coho Partners Ltd., Swiss National Bank, American Century Companies Inc., Northern Trust Corp and Legal & General Group Plc. Company insiders that have sold Abbott Laboratories company stock in the last year include Alejandro D Wellisch, Brian J Blaser, Daniel Gesua Sive Salvadori, Hubert L Allen, Jaime Contreras, Jared Watkin, Miles D White, Roger Bird, Sharon J Bracken and Stephen R Fussell. View Insider Buying and Selling for Abbott Laboratories.

ABT stock was purchased by a variety of institutional investors in the last quarter, including BlackRock Inc., Montag & Caldwell LLC, Ceredex Value Advisors LLC, Eaton Vance Management, Summit Trail Advisors LLC, Mackay Shields LLC, CIBC World Markets Inc. and Franklin Resources Inc.. Company insiders that have bought Abbott Laboratories stock in the last two years include Brian J Blaser, Daniel J Starks, Miles D White, Robert B Ford and Sally E Blount. View Insider Buying and Selling for Abbott Laboratories.

Shares of ABT can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

One share of ABT stock can currently be purchased for approximately $62.51.

Abbott Laboratories has a market capitalization of $108.42 billion and generates $27.39 billion in revenue each year. The healthcare product maker earns $477 million in net income (profit) each year or $2.50 on an earnings per share basis. Abbott Laboratories employs 99,000 workers across the globe.

Abbott Laboratories' mailing address is 100 ABBOTT PARK ROAD D-322 AP6D, ABBOTT PARK IL, 60064. The healthcare product maker can be reached via phone at 224-667-6100.